Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Clinical trial NCT03326336 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03326336
- Sponsor
- GenSight Biologics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-26
- Primary completion
- 2027-10-26
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.